A 10-residue peptide from durum wheat promotes a shift from a Th1-type response toward a Th2-type response in celiac disease

American Journal of Clinical Nutrition

Volumn 87, Issue 2, 2008, Pages 415-423

  Silano, Marco ^a   Di Benedetto, Rita ^a   Maialetti, Francesca ^a   De Vincenzi, Alessandro ^b   Calcaterra, Roberta ^c   Trecca, Antonello ^d   De Vincenzi, Massimo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^d International Health Care Center   (Italy)

Author keywords

Celiac disease; Gluten specific T cells; Th1 to Th2 shift

Indexed keywords

ALANINE; ASPARTIC ACID; GAMMA INTERFERON; GLIADIN; GLUTAMINYLGLUTAMINYLPROLYLGLUTAMINYLASPARTYLALANYLVALYLGLUTAMINYLPROLYLPHENYLALNINE; GLUTEN; INTERLEUKIN 10; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOIMMUNE DISEASE; CELIAC DISEASE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WHEAT;

TRITICUM TURGIDUM SUBSP. DURUM;

EID: 38949195004     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/87.2.415     Document Type: Article

References (40)

1. Jabri B, Kasarda DD, Green PH. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 2005;206:219-31.
2. Jabri B, Sollid LM. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006;3:516-25.
3. Sollid LM. Celiac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002;2:647-55.
4. Vader LW, Stepniak DT, Bunnik EM, et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003;12:1105-13.
5. Tollefsen S, Arentz-Hansen H, Fleckenstein B, et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest 2006;116:2226-36.
6. Molberg O, Solheim Flaete N, Jensen T et al. Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 2003;125:337-44.
7. Arentz-Hansen H, McAdam SN, Molberg O et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002;123:803-9.
8. Van de Wal Y, Kooy YM, van Veelen P, et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 199;29:3133-9.
9. Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005;128:S79-86.
10. Viljamaa M, Kaukinen K, Pukkala E. Hervonen K, Reunala T, Collin P. Malignancies and mortality in patients with celiac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006;38:374-80.
11. Card TR, West J, Holmes GK. Risk of malignancy in diagnosed celiac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004;20:769-75.
12. Anderson RP, van Heel DA, Tye-Din JA, et al. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in celiac disease. Gut 2006;55:485-91.
13. Molberg O, Uhlen AK, Jensen T, et al. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005;128:393-401.
14. Monteleone I, Monteleone G, Del Vecchio Blanco G, et al. Regulation of the T helper cell type 1 transcription factor T-bet in celiac disease mucosa. Gut 2004;53:1090-5.
15. Lahat N, Shapiro S, Karban A, Gerstein R, Kinarty A, Lerner A. Cytokine profile in celiac disease. Scand J Immunol 1999;49:441-6.
16. Sai P, Rivereau AS, Granier C Haertle T, Martignat L. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes. Clin Exp Immunol 1996;105:330-7.
17. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006;203:401-12.
18. Viardot A, Grey ST, Mackay F, Crisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T Helper 2 phenotype. Endocrinology 2007;148:346-53.
19. Salvati VM, Mazzarella G, Gianfrani C, et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured celiac intestinal mucosa. Gut 2005;54:46-53.
20. Silano M, Di Benedetto R, Trecca A, et al. A decapeptide from durum wheat prevents celiac peripheral lymphocytes from activation by gliadin peptides Pediatr Res 2007;61:67-71.
21. De Ritis G, Occorsio P, Auricchio S, Gramenzi S, Morisi G, Silano V. Toxicity of wheat flour proteins and protein-derived peptides for in vitro developing intestine from rat fetus. Pediatr Res 1979;13:1255-61.
22. De Vincenzi M, Gasbarrini G, Silano V. A small peptide from durum wheat gliadin prevents cell agglutination induced by prolamin-peptides toxic in celiac disease. Toxicology 1997;120:207-13.
23. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in celiac disease. Lancet 2003;362:30-7.
24. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000;191:603-12.
25. Molberg O, McAdam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998;4:713-7.
26. Van de Wal Y, Kooy J, van Veelen P, et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998;161:1585-8.
27. Quarsten H, Molberg O, Fugger L, McAdam SN, Sollid LM. HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. Eur J Immunol 1999;29:2506-14.
28. Molberg O, McAdam SN, Lundin KEA, et al. Studies on gliadin specific T cells in celiac diasease. In: Marsh MN, ed. Methods in molecular medicine. Vol 41: Celiac disease: methods and protocols. Totowa, NJ: Humana Press, 2000:105-24.
29. Ellis HJ, Pollock EL, Engel W, et al. Investigation of the putative immunodominant T cell epitopes in celiac disease. Gut 2003;52:212-7.
30. De Vincenzi M, Stammati A, Luchetti R, Silano M, Gasbarrini G, Silano V. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562(S) cells. Toxicology 1998;127:97-106.
31. Cornell HJ, Maxwell RJ. Amino acid composition of gliadin fractions which may be toxic to individuals with coeliac disease. Clin Chim Acta 1982;123:311-9.
32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
33. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000;10:542-50.
34. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol 200;116:459-62.
35. Forsberg G, Hernell O, Melgar S, et al. Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002;123:667-78.
36. Bolin DR, Swain AL, Sarabu R, et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 2000;43:2135-48.
37. Xia J, Siegel M, Bergseng E, Sollid LM, Khosla C. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 2006;128:1859-67.
38. Vader LW, de Ru A, van der Wal Y, et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002;195:643-9.
39. Biagi F, Ellis HJ, Parnell ND, et al. A non-toxic analogue of a celiacactivating gliadin peptide: a basis for immunomodulation? Aliment Pharmacol Ther 1999;13:945-50.
40. Kersh GJ, Miley MJ, Nelson CA, et al. Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 2001;166:3345-54.